Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 66Neutropenia 16Triple Negative Breast Neoplasms 8Breast Neoplasms, Male 6Inflammatory Breast Neoplasms 4Ovarian Neoplasms 3Lung Neoplasms 3Neoplasms 2Febrile Neutropenia 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Pain 1Melanoma 1Lymphoma, Non-Hodgkin 1Locally Advanced Breast Cancer 1HER2-positive Breast Cancer 1HER2-Positive Early Stage Breast Cancer 1Fever 1Early Stage Breast Cancer 1Colorectal Neoplasms 1Chemotherapy-Induced Febrile Neutropenia 1Carcinoma, Renal Cell 1Carcinoma 1Breast Diseases 1Breast Cancer Metastatic 1Breast Cancer Female 1Adenocarcinoma 1

Interventions

pembrolizumab 44Cyclophosphamide 21Nivolumab 18fludarabine 10durvalumab 8Paclitaxel 8Magnetic Resonance Spectroscopy 8Interleukin-2 8Docetaxel 8aldesleukin 7Radiosurgery 7Ipilimumab 7spartalizumab 6poly ICLC 6fludarabine phosphate 6atezolizumab 6Specimen Handling 6Radiotherapy 6Carboplatin 6cemiplimab 5Drug Therapy 5Cisplatin 5Biopsy 5Temozolomide 4Immune Checkpoint Inhibitors 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3avelumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × pegfilgrastim × Breast × Clear all
NCT02650635 2018-09-05

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Mayo Clinic

Phase 1 Terminated
4 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡